A new reconstitutable oral paediatric hydrocortisone solution containing hydroxypropyl-β-cyclodextrin

Drug Development and Industrial Pharmacy

Volumn 39, Issue 7, 2013, Pages 1028-1036

  Orlu Gul, Mine ^a,b   Fisco, Giacomo ^a,c   Parmar, Dipesh ^a   Gill, Hardyal ^a   Tuleu, Catherine ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Age appropriate formulation; Hydrocortisone; Paediatrics; Reconstitutable; Taste assessment

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CITRIC ACID; HYDROCORTISONE; METHYL PARABEN; NEOTAME; SODIUM; SORBATE POTASSIUM; SWEETENING AGENT;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STORAGE; DRY POWDER; EXCIPIENT COMPATIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; NORMAL HUMAN; PH; RECONSTITUTABLE DRY POWDER; SAFETY; SOLUBILITY; SOLUBILIZATION; TASTE DISCRIMINATION;

ADMINISTRATION, ORAL; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; HYDROCORTISONE; HYDROGEN-ION CONCENTRATION; SOLUTIONS; TASTE;

EID: 84878858427     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.696654     Document Type: Article

References (40)

1. Debono M, Price JN, Ross RJ. (2009). Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab, 23:221-232.
2. Merke DP, Bornstein SR. (2005). Congenital adrenal hyperplasia. Lancet, 365:2125-2136.
3. Hindmarsh PC. (2009). Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab, 23:193-208.
4. BNFC. (2011). British national formulary for children. London: BMJ Publishing Group, Pharmaceutical Press, and RCPCH Publications.
5. Claahsen-van der Grinten HL, Stikkelbroeck NM, Otten BJ, Hermus AR. (2011). Congenital adrenal hyperplasia-pharmacologic interventions from the prenatal phase to adulthood. Pharmacol Ther, 132:1-14.
6. Smyth JA. (2010). The NEWT guidelines for administration of medication to patients with enteral feeding tubes or swallowing difficulties. North East Wales:NHS Trust.
7. Jackson M, Lowey A. (2010). Handbook of extemporaneous preparation: a guide to pharmaceutical compounding. London: Pharmaceutical Press, 209-216.
8. Rogerson A, Hiom S, Smith JC, Conway BR. (2010). Physical stability of extemporaneously prepared oral hydrocortisone suspensions. UK-PharmSci 2010 - The Science of Medicines, Nottingham, UK: Wiley, 1460.
9. Merke DP, Cho D, Calis KA, Keil MF, Chrousos GP. (2001). Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. J Clin Endocrinol Metab, 86:441-445.
10. Heames K, Shah UU, Riby P, Blair J, Ford J. (2009). Accuracy of 2.5 mg hydrocortisone doses from quatered 10 mg tablets. Proceedings of the 37th meeting of the British society for paediatric endocrinology and diabetes, reading, UK.
11. European Medicines Agency Revised priority list for studies into off-patent paediatric medicinal products for the 5th Call 2011 of the 7th framework programme of the European commission. EMA/480197/2010 Rev. 2010 - update 17/11/2010, London, 2010.
12. European Medicines Agency Report on the survey of all paediatric uses of medicinal products in Europe. EMA/794083/2009, London, 2010. http://www.ema.europa.eu/docs/en-GB/document-library/ Report/2011/01/ WC500101006.pdf. Accessed on 11 February 2012.
13. Trissel LA. (2009). Trissel's stability of compounded formulations. Washington, DC: American Pharmacists Association, 277-282.
14. Fawcett JP, Boulton DW, Jiang R, Woods DJ. (1995). Stability of hydrocortisone oral suspensions prepared from tablets and powder. Ann Pharmacother, 29:987-990.
15. Fleisher D, Johnson KC, Stewart BH, Amidon GL. (1986). Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution. J Pharm Sci, 75:934-939.
16. Brewster ME, Loftsson T. (2007). Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev, 59:645-666.
17. Challa R, Ahuja A, Ali J, Khar RK. (2005). Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech, 6:E329-E357.
18. Otero-Espinar FJ, Luzardo-Alvarez A, Blanco-Méndez J. (2010). Cyclodextrins: more than pharmaceutical excipients. Mini Rev Med Chem, 10:715-725.
19. Hendeles L. (2003). Selecting a systemic corticosteroid for acute asthma in young children. J Pediatr, 142:S40-S44.
20. Kim MK, Yen K, Redman RL, Nelson TJ, Brandos J, Hennes HM. (2006). Vomiting of liquid corticosteroids in children with asthma. Pediatr Emerg Care, 22:397-401.
21. Lucas-Bouwman ME, Roorda RJ, Jansman FG, Brand PL. (2001). Crushed prednisolone tablets or oral solution for acute asthma? Arch Dis Child, 84:347-348.
22. Ishizaka T, Okada S, Tokuyama E, Mukai J, Uchida T. (2008). Suppression of bitterness and improvement of palatability of commercial prednisolone powder. Chem Pharm Bull, 56:1395-1399.
23. Woertz K, Tissen C, Kleinebudde P, Breitkreutz J. (2010). Rational development of taste masked oral liquids guided by an electronic tongue. Int J Pharm, 400:114-123.
24. Motola S, Agisim RG, Mogavero A. (1991). American home products corporation. palatable ibuprofen solutions. United States Patent 5,024,997.
25. European Medicines Agency, Committee For Medicinal Products For Human Use Reflection Paper: Formulations Of Choice For The Paediatric Population. EMEA/CHMP/PEG/194810/2005. London, 2006. http://www.ema.europa.eu/docs/en-GB/ document- library/Scientific-guideline/2009/09/WC500003782.pdf. Accessed on 11 February 2012.
26. StataCorp. (2011). Stata statistical software: Release 12. College Station, TX: StataCorp LP.
27. European Medicines Agency, ICH Topic Q 2 (R1) Validation of analytical procedures: text and methodology. note for guidance on validation of analytical procedures: text and methodology. CPMP/ICH/381/95. London, 1995. http://www.emea.europa.eu/ docs/en-GB/document-library/Scientific-guideline/ 2009/09/ WC500002662.pdf. Accessed on 11 February 2012.
28. Microbiological quality of pharmaceutical preparations for oral administration European Pharmacopoeia 7.0, Strasbourg, 2011;507.
29. European Medicines Agency, Committee for proprietary medicinal products note for guidance on in-use stability testing of human medicinal products. CPMP/QWP/2934/99. London, 2001. http:// www.ema.europa.eu/docs/en-GB/document- library/Scientific- guideline/2009/09/WC500003475.pdf. Accessed on 11 February 2012.
30. Gupta VD. (2010). Chemical stability of hydrocortisone in humco simple syrup and ora-sweet vehicle. Int J Pharm Compd, 76-77.
31. EFSA. (2007). Neotame as a sweetener and flavour enhancer. EFSA J, 581:1-43.
32. Rowe RC, Sheskey PJ, Quinn M. (2011). Pharmaceutical excipients. London: Pharmaceutical Press.
33. Scheler S, Saupe S, Herre A, Fahr A. (2010). Preservation of liquid drug preparations for oral administration. J Pharm Sci, 99:357-367.
34. Wilson R. (2007). Sweeteners. Oxford: Blackwell Publishing.
35. Schiffman SS, Sattely-Miller EA, Bishay IE. (2008). Sensory properties of neotame: comparison with other sweeteners. In: Weerasinghe DK, DuBois GE, ed. Sweetness and Sweeteners. Washington, DC: American Chemical Society, pp 511-529.
36. Nofre C, Tinti J-M. (2000). Neotame: discovery, properties, utility. Food Chemistry, 69:245-257.
37. Meilgaard MC, Civille GV, Carr BT. (2007) Sensory evaluation techniques. Florida: CRC Press: Boca Raton.
38. Mitchell JC, Counselman FL. (2003). A taste comparison of three different liquid steroid preparations: prednisone, prednisolone, and dexamethasone. Acad Emerg Med, 10:400-403.
39. Lund W. (1994). The pharmaceutical codex, (Edn. 12th). London: The Pharmaceutical Press, 277-283.
40. Glass BD, Haywood A. (2006). Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. J Pharm Pharm Sci, 9:398-426.